Outcome Terapi Covid-19 pada Pasien yang Mendapatkan Antikoagulan Profilaksis di RSPAL Dr. Ramelan Surabaya: Outcome Covid-19 Anticoagulant Prophylaxis in Covid-19 Patients at Dr. Ramelan Naval Center Hospital Surabaya

Rizki Damayanti; Anita Purnamayanti; Aguslina Kirtishanti; Ediyono Ediyono

doi:10.33084/jsm.v8i3.3727

Authors

Rizki Damayanti Universitas Surabaya
Anita Purnamayanti Universitas Surabaya https://orcid.org/0000-0003-4544-7052
Aguslina Kirtishanti Universitas Surabaya https://orcid.org/0000-0002-1690-2733
Ediyono Ediyono Rumah Sakit Pusat TNI Angkatan Laut Dr. Ramelan Surabaya

DOI:

https://doi.org/10.33084/jsm.v8i3.3727

Keywords:

Anticoagulan, COVID-19, LMWH, UFH, Fondafarinoux, Rivaroxaban

Abstract

Complications of thrombotic and hemorrhagic coagulation often occur in Covid-19 patients, so it is advisable to provide anticoagulant therapy, accompanied by monitoring of parameters of coagulation abnormalities, including D-Dimer. This study aims to determine the outcome of therapy for Covid-19 in patients with anticoagulant prophylaxis use in RSPAL Dr. Ramelan Surabaya. This study is a retrospective descriptive study based on medical records of Covid-19 patients from June-August 2021. The sample in this study was subjects aged >18 years who were confirmed positive for Covid-19 based on RT-PCR, with comorbid or without comorbidities, and received anticoagulant therapy. Then, this study did not include subjects who were pregnant or with malignancy/acute conditions. From 134 research samples, it was found that the use of anticoagulants using a single anticoagulant (n=131, 97.76%) was more widely used, with the most frequently used types being enoxaparin (n=68, 50.75%), and heparin (n=48, 35,8%). In conclusion, the recovery percentage in Covid-19 subjects with anticoagulant therapy was 77.61%, and the percentage of mortality was 22,39%.

Downloads

Download data is not yet available.

References

World Health Organization. 2015. Ageing Revised the Age Standard. Diakses pada 05 Juli 2022, dari https://www.who.int/health-topics/ageing#tab=tab_1

Covid19.go.id. 04 Juli 2022. Peta Sebaran Covid-19 di Indonesia. Diakses pada 05 Juli 2022, dari https://covid19.go.id/peta-sebaran

Bels J.L.M, Van Kuijk S.M.J, Ghossein-Doha C. et al. 2021. Decreased Serial Scores of Severe Organ Failure Assessment are Associated with Survival in Mechanically Ventilated Patients; the Retrospective Maastricht Intensive Cave Covid Cohort.. J Crit Care. 2021;62;38-45. https://doi.org/10.1016/j.jcrc.2020.11.006

Luis OP, Davide C, Gilles M et al,. 2021. Coronavirus Disease 2019-Associated Trombosis and Coagulophaty: Review of the Pathophysiologycal Characteristic and Implications for Antithrombotic Management. Journal of the American Heart Association. Vol.10, No. 3. https://doi.org/10.1161/JAHA.120.019650

Wahid L, Thomas L,. 2021. Anticoagulant Therapy in Patients Hospitalized With Covid-19. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2021.6212

Berger JS, Kunichoff D, Adhikari Sm Ahuja T et al. 2020. Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients with Covid-19. Atherioscler Thromb Vasc Biol. 2020;40(10);2539-47. https://doi.org/10.1161/atvbaha.120.314872

Ikatan Dokter Indonesia. 2020. Rekomendasi IDI Pemberian Antikoagulan Profilaksis pada Paisen Covid-19 yang Dirawat di Rumah Sakit. Jakarta.

Rozenfeld Y, Beam J, Maier H et al. 2020. A Model of Disparities: Risk Factor Associated with Covid-19 Infection. International Journal for Equity in Health https://equityhealthj.biomedcentral.com/articles/10.1186/s12939-020-01242-z#citeas

Kai Liu, Ying Chen, Ruzheng Lin et al,. 2020. Clinical Features of Covdi-19 in Elderly Patients; a Comparison with Young and Middle-aged Patients. J Infect 80(6):e14-e18 https://doi.org/10.1016%2Fj.jinf.2020.03.005

Eduardo F, Manuel F, Marcelo A et al. 2017. SImmune System Dysfunction in the Elderly. Biomedical Science. 89:1 https://doi.org/10.1590/0001-3765201720160487

PDPI, PERKI, PAPDI, PERDATIN, IDAI. 2021. Revisi Protokol Tatalaksana Covid-19. 14 Juli-2021

Jiang L, Li Y, Du H et al. 2021. Effect of Anticoagulant Administration on the Mortality of Hospitalized Patient with Covid-19: An Update Systematic Review and Meta Analysis. Front Med (Lausanne). 20209:698935. https://doi.org/10.3389%2Ffmed.2021.698935

Kumar D, Kaimaparambil V, Chandralekha S, Lalchandani J. Oral Rivaroxaban in the Prophylaxis of COVID-19 Induced Coagulopathy. J Assoc Physicians India. 2022 Feb;70(2):11-12. PMID: 35436816.

Albani F, Sepe L, Fusina F et al. 2020. Thromboprophylaxis with Enoxaparin is Associated with a Lower Death Rate in Patients Hospitalized with SARS-CoV-2 Infection. A Cohort Study. eClinicalMedicine. Vol. 27 https://doi.org/10.1016/j.eclinm.2020.100562

Barnes G, Burnett A, Blumenstein M et al. 2020. Thromboembolism and Anticoagulant Therapy During the Covid-19 Pandemic: Interim Clinical Guidance from the Anticoagulant Forum. Journal of Thrombosis and Thrombolysis. 50, 72-81 https://doi.org/10.1007/s11239-020-02138-z

Miesbach W, Makris M. 2020. Covid-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. SagePub- Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177%2F1076029620938149

Poterucha TJ, Libby P, Goldhaber S. 2017. More than an Anticoagulant: Do Heparins have Direct anti-inflamatory Effects?. Thromb Haemost 2017;117(03):437-444 https://doi.org/10.1160/TH16-08-062

Qian Z, Lu S, Luo X et al. 2021. Mortality and Clinical Interventions in Critically Ill Patient with Coronavirus Disease 2019: a Systematic Review and Meta-Analysis. Front Med (Lausanne). 2021;8:635560 https://doi.org/10.3389%2Ffmed.2021.635560